510(k) Report

510(k) · Cleared

Cleared

Inomax Dsir (Delivery System)

K130605510(k) SpecialCleared May 2, 201356-day reviewClass II21 CFR 868.5165

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Ino Therapeutics · MRN Apparatus, Nitric Oxide Delivery

Cleared on May 2, 2013 as substantially equivalent to K061901 (Ino Therapeutics, 2006) and 11 other predicates after a 56-day review. Its family tree reaches back 10 generations to 2001. 6 later devices descend from it.

Decided
May 2, 2013
Review
56 days
Class
Class II
Product code
MRN
Recalls
None
Predicates
12

Its longest line of descent runs back 10 generations to K003665 (2001). 18 ancestors in all, the oldest K000186 (2000). 6 later devices descend from it, 1 citing it directly.

  1. Root · 10 generations backK003665 Fadassi Medical FM-1 NO BlenderFadasis Medical, Inc. · 2001
  2. 6 generations between
  3. 3 generations backK110635 Inomax DS (IR) (Delivery System)Ino Therapeutics, LLC/Dba Ikaria · 2011
  4. 2 generations backK113272 Inomax DS (Delivery SystemsIno Therapeutics, LLC/Dba Ikaria · 2012
  5. 1 generation backK121021 Inomax DS (Delivery System)Ino Therapeutics · 2012
  6. This deviceK130605 Inomax Dsir (Delivery System)Ino Therapeutics · 2013
  7. Descendant · cites it directly · 5 of its ownK131686 Inomax Dsir (Delivery System)Ino Therapeutics/Ikaria · 2013 · Recalled
  8. Descendant · 2 generations on · 3 of its ownK200389 INOmax DSIR PlusMallinckrodt Manufacturing, LLC · 2020
  9. Descendant · 3 generations on · 1 of its ownK212409 Ulspira TS Nitric Oxide Therapy SystemAirgas Therapeutics · 2023
  10. Descendant · 4 generations on · 0 of its ownK242374 ULSPIRA TS™ Nitric Oxide Therapy SystemAirgas Therapeutics, LLC · 2025
  11. Descendant · 2 generations on · 0 of its ownK211153 Inomax DSIRMallinckrodt Manufacturing, LLC · 2023
Show all 10 generations
  1. Root · 10 generations backK003665 Fadassi Medical FM-1 NO BlenderFadasis Medical, Inc. · 2001
  2. 9 generations backK011874 Fadasis Medical FM-1 NO BlenderFadasis Medical, Inc. · 2001
  3. 8 generations backK052663 Ino Therapeutics Inoblender, Model 10004Ino Therapeutics · 2005
  4. 7 generations backK061901 Ino Therapeutics Inomax DS (Delivery System), Model 10003Ino Therapeutics · 2006 · Recalled
  5. 6 generations backK070867 Inomax DS (Delivery System), Model 10003Ino Therapeutics, LLC · 2007
  6. 5 generations backK071516 Inomax DSIno Therapeutics, LLC · 2007
  7. 4 generations backK080484 Inomax DS (Delivery System), Model 10003Ino Therapeutics · 2008
  8. 3 generations backK110635 Inomax DS (IR) (Delivery System)Ino Therapeutics, LLC/Dba Ikaria · 2011
  9. 2 generations backK113272 Inomax DS (Delivery SystemsIno Therapeutics, LLC/Dba Ikaria · 2012
  10. 1 generation backK121021 Inomax DS (Delivery System)Ino Therapeutics · 2012
  11. This deviceK130605 Inomax Dsir (Delivery System)Ino Therapeutics · 2013

Showing 5 of 6 descendants. See all descendants

Descendants cleared per year

2013: 12015: 12020: 12023: 22025: 1
2013high 2 (2023) · low 0 (2014)2026

Most influential descendants

Showing 5 of 6 · See all
  • K131686Inomax Dsir (Delivery System)Ino Therapeutics/Ikaria · 2013 · cites it directly5descendants
  • K200389INOmax DSIR PlusMallinckrodt Manufacturing, LLC · 2020 · 2 generations on3descendants
  • K212409Ulspira TS Nitric Oxide Therapy SystemAirgas Therapeutics · 2023 · 3 generations on1descendant
  • K242374ULSPIRA TS™ Nitric Oxide Therapy SystemAirgas Therapeutics, LLC · 2025 · 4 generations on0descendants
  • K211153Inomax DSIRMallinckrodt Manufacturing, LLC · 2023 · 2 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−10K003665Fadassi Medical FM-1 NO BlenderFadasis Medical, Inc.2001—
−9K011874Fadasis Medical FM-1 NO BlenderFadasis Medical, Inc.2001—
−8K052663Ino Therapeutics Inoblender, Model 10004Ino Therapeutics2005—
−7K061901Ino Therapeutics Inomax DS (Delivery System), Model 10003Ino Therapeutics20063
−6K070867Inomax DS (Delivery System), Model 10003Ino Therapeutics, LLC2007—
−5K071516Inomax DSIno Therapeutics, LLC2007—
−4K080484Inomax DS (Delivery System), Model 10003Ino Therapeutics2008—
−3K110635Inomax DS (IR) (Delivery System)Ino Therapeutics, LLC/Dba Ikaria2011—
−2K113272Inomax DS (Delivery SystemsIno Therapeutics, LLC/Dba Ikaria2012—
−1K121021Inomax DS (Delivery System)Ino Therapeutics2012—
0 (this device)K130605Inomax Dsir (Delivery System)Ino Therapeutics2013—
+1K131686Inomax Dsir (Delivery System)Ino Therapeutics/Ikaria20134
+2K200389INOmax DSIR PlusMallinckrodt Manufacturing, LLC2020—
+3K212409Ulspira TS Nitric Oxide Therapy SystemAirgas Therapeutics2023—
+4K242374ULSPIRA TS™ Nitric Oxide Therapy SystemAirgas Therapeutics, LLC2025—
+2K211153Inomax DSIRMallinckrodt Manufacturing, LLC2023—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
200020
200310
200810
200910
201020
201110

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201310
201510
202010
202320
202510
FIG. 1 — Lineage of K130605, 2001–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MRN? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MRN device

  1. #1 K242374 ULSPIRA TS™ Nitric Oxide Therapy Systemscore 12.6 · 14 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (12)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K061901Ino Therapeutics Inomax DS (Delivery System), Model 10003
Summary page 1
…Device Classification: Class It1-21 CER 868.5165 Product Code: MRN (Primary), MRQ MRP Predicate Device(s) K06 1901, K070867, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635,…
Ino Therapeutics20063
*K070867Inomax DS (Delivery System), Model 10003
Summary page 1
…vice Classification: Class It1-21 CER 868.5165 Product Code: MRN (Primary), MRQ MRP Predicate Device(s) K06 1901, K070867, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635,…
Ino Therapeutics, LLC2007—
*K071516Inomax DS
Summary page 1
…sification: Class It1-21 CER 868.5165 Product Code: MRN (Primary), MRQ MRP Predicate Device(s) K06 1901, K070867, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635,…
Ino Therapeutics, LLC2007—
*K080484Inomax DS (Delivery System), Model 10003
Summary page 1
…: Class It1-21 CER 868.5165 Product Code: MRN (Primary), MRQ MRP Predicate Device(s) K06 1901, K070867, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635,…
Ino Therapeutics2008—
*K081691Inomax DS (Delivery System)
Summary page 1
…Class It1-21 CER 868.5165 Product Code: MRN (Primary), MRQ MRP Predicate Device(s) K06 1901, K070867, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635, K…
Ino Therapeutics, LLC2008—
*K090958Inomax DS (Delivery System)
Summary page 1
…MRN (Primary), MRQ MRP Predicate Device(s) K06 1901, K070867, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635, K 113272, K121021 Description of Device The…
Ino Therapeutics, LLC2009—
*K092545Inomax DS (Delivery System), Model 10003
Summary page 1
…MRN (Primary), MRQ MRP Predicate Device(s) K06 1901, K070867, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635, K 113272, K121021 Description of Device The INOmax DS…
Ino Therapeutics, LLC2010—
*K093922Inomax DS
Summary page 1
…MRN (Primary), MRQ MRP Predicate Device(s) K06 1901, K070867, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635, K 113272, K121021 Description of Device The INOmax DSIR®0 uses…
Ino Therapeutics20101
*K110344Inomax Dsir (Delivery System)
Summary page 1
…ary), MRQ MRP Predicate Device(s) K06 1901, K070867, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635, K 113272, K121021 Description of Device The INOmax DSIR®0 uses a "dual-c…
Ino Therapeutics2011—
*K110635Inomax DS (IR) (Delivery System)
Summary page 1
…MRP Predicate Device(s) K06 1901, K070867, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635, K 113272, K121021 Description of Device The INOmax DSIR®0 uses a "dual-channel" de…
Ino Therapeutics, LLC/Dba Ikaria2011—
*K113272Inomax DS (Delivery Systems
Summary page 1
…901, K070867, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635, K 113272, K121021 Description of Device The INOmax DSIR®0 uses a "dual-channel" design to ensure the safe…
Ino Therapeutics, LLC/Dba Ikaria2012—
*K121021Inomax DS (Delivery System)
Summary page 1
…67, K07 1516, K080484, K08 1691, K090958, K092545, K093922, K1 10344, K1 10635, K 113272, K121021 Description of Device The INOmax DSIR®0 uses a "dual-channel" design to ensure the safe delivery…
Ino Therapeutics2012—
†K081447Fourth Gas Module with CO2 for Primus US ApolloDraeger Medical AG & Co. KG20081

Also cleared against K061901: 13 other devices →

What descends from it? (6)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K131686Inomax Dsir (Delivery System)Ino Therapeutics/Ikaria20135

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 12 years and passes through 4 companies; a new generation was cleared every 8 months on median.
  • 3 of the 18 ancestors have a recall of any class.
  • Of its descendants, K131686 (Ino Therapeutics/Ikaria, 2013) has gone furthest, with 5 descendants of its own.
  • 13 other devices also cite its predicate K061901.

How does its category compare?

All MRN devices

MRN Apparatus, Nitric Oxide Delivery: FDA decisions, review times, recalls and adverse event reports over 20 years. 2013, this device’s year, is highlighted.

FDA decisions per year · MRN

2in 2025

2007: 22008: 22009: 12010: 22011: 22012: 32013: 22015: 12018: 12020: 32022: 12023: 42024: 22025: 2
2007high 4 (2023) · low 0 (2014)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MRN

566in 2023

2012: 117 days median2020: 84 days median2023: 566 days median
2007high 566 (2023) · low 84 (2020)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · MRN

2in 2025

2010: 22014: 12023: 12025: 2, 2 Class I2026 (partial year): 2
2007high 2 (2010) · low 0 (2007)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · MRN

155in 2025

2007: 32008: 92009: 102010: 1552011: 552012: 242013: 322014: 792015: 1562016: 942017: 1062018: 1382019: 1442020: 1992021: 2212022: 1152023: 992024: 1382025: 155
2007high 221 (2021) · low 3 (2007)2025

MAUDE reports naming product code MRN, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—03
20082—09
20091—010
20102—2155
20112—055
20123117024
20132—032
20140—179
20151—0156
20160—094
20170—0106
20181—0138
20190—0144
20203840199
20210—0221
20221—0115
20234566199
20242—0138
20252—2 (2)155
20260—2—

What is it indicated for?

The INOmax® DS delivery system delivers INOmax® (nitric oxide for inhalation) therapy gas into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath. It uses a specially designed injector module, which enables tracking of the ventilator waveforms and the delivery of a synchronized and proportional dose of NO. It may be…

Read the full statement (206 words)

The INOmax® DS delivery system delivers INOmax® (nitric oxide for inhalation) therapy gas into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath. It uses a specially designed injector module, which enables tracking of the ventilator waveforms and the delivery of a synchronized and proportional dose of NO. It may be used with most ventilators.

The INOmax® DS provides continuous integrated monitoring of inspired O2, NO2, and NO, and a comprehensive alarm system.

The INOmax® DS incorporates a battery that provides up to 6 hours of uninterrupted NO delivery in the absence of an external power source.

The INOmax® DS includes a backup NO delivery capability that provides a fixed flow of 250 mL/min of NO which along with user supplied 10 L/min of oxygen provides 20 ppm in the gas flow to a patients breathing circuit. It may also use the INOblender® for backup.

The target patient population is controlled by the drug labeling for INOmax® and is currently neonates. The primary targeted clinical setting is the Neonatal Intensive Care Unit (NICU) and secondary targeted clinical setting is the transport of neonates.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K130605: Inomax Dsir (Delivery System).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K130605

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026